메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Lim Sung Hee (Division of Hematology-Oncology Department of Medicine Soonchunhyang University Bucheon Hospital Bucheon Korea.) Kim Han Jo (Division of Hematology-Oncology Department of Medicine Soonchunhyang University Cheonan Hospital Cheonan Korea.) Kim Se Hyung (Division of Hematology-Oncology Department of Medicine Soonchunhyang University Bucheon Hospital Bucheon Korea.) Choi Seong Hyeok (Division of Hematology-Oncology Department of Medicine Soonchunhyang University Bucheon Hospital Bucheon Korea.) Kim Bora (Division of Hematology-Oncology Department of Medicine Soonchunhyang University Bucheon Hospital Bucheon Korea.) Kim Ji Youn (Division of Hematology-Oncology Department of Medicine Soonchunhyang University Bucheon Hospital Bucheon Korea.) Ji Young Sok (Division of Hematology-Oncology Department of Medicine Soonchunhyang University Bucheon Hospital Bucheon Korea.) Kim Tark (Division of Infectious Disease Department of Medicine Soonchunhyang University Bucheon Hospital Bucheon Korea.) Choo Eun Ju (Division of Infectious Disease Department of Medicine Soonchunhyang University Bucheon Hospital Bucheon Korea.) Jung Jung Chan (Department of Medical Biotechnology Soonchunhyang University Asan Korea.) Moon Ji Eun (Department of Biostatistics Clinical Trial Center Soonchunhyang University Bucheon Hospital Bucheon Korea.) Kim Chan Kyu (Division of Hematology-Oncology Department of Medicine Soonchunhyang University Bucheon Hospital Bucheon Korea.) Park Seong Kyu (Division of Hematology-Oncology Department of Medicine Soonchunhyang University Bucheon Hospital Bucheon Korea.) Yun Jina (Division of Hematology-Oncology Department of Medicine Soonchunhyang University Bucheon Hospital Bucheon Korea.)
저널정보
대한의학회 Journal of Korean Medical Science Journal of Korean Medical Science Vol.38 No.13
발행연도
2023.4
수록면
1 - 12 (12page)
DOI
10.3346/jkms.2023.38.e103

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Background: Although the primary vaccine coverage rate for coronavirus disease 2019 (COVID-19) in South Korea has exceeded 80%, the coronavirus continues to spread, with reports of a rapid decline in vaccine effectiveness. South Korea is administering booster shots despite concerns about the effectiveness of the existing vaccine. Methods: Neutralizing antibody inhibition scores were evaluated in two cohorts after the booster dose. For the first cohort, neutralizing activity against the wild-type, delta, and omicron variants after the booster dose was evaluated. For the second cohort, we assessed the difference in neutralizing activity between the omicron infected and uninfected groups after booster vaccination. We also compared the effectiveness and adverse events (AEs) between homologous and heterologous booster doses for BNT162b2 or ChAdOx1 vaccines. Results: A total of 105 healthcare workers (HCWs) that were additionally vaccinated with BNT162b2 at Soonchunhyang University Bucheon Hospital were enrolled in this study. Significantly higher surrogate virus neutralization test (sVNT) inhibition (%) was observed for the wild-type and delta variants compared to sVNT (%) for the omicron after the booster dose (97%, 98% vs. 75%; P < 0.001). No significant difference in the neutralizing antibody inhibition score was found between variants in the BNT/BNT/BNT group (n = 48) and the ChA/ChA/BNT group (n = 57). Total AEs were not significantly different between the ChA/ ChA/BNT group (85.96%) and the BNT/BNT group (95.83%; P = 0.11). In the second cohort with 58 HCWs, markedly higher sVNT inhibition to omicron was observed in the omicroninfected group (95.13%) compared to the uninfected group (mean of 48.44%; P < 0.001) after four months of the booster dose. In 41 HCWs (39.0%) infected with the omicron variant, no difference in immunogenicity, AEs, or effectiveness between homogeneous and heterogeneous boosters was observed. Conclusion: Booster vaccination with BNT162b2 was significantly less effective for the neutralizing antibody responses to omicron variant compared to the wild-type or delta variant in healthy population. Humoral immunogenicity was sustained significantly high after 4 months of booster vaccine in the infected population after booster vaccination. Further studies are needed to understand the characteristics of immunogenicity in these populations.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0